CSPC Pharmaceutical Group (1093) Earnings: 1H Sales Hit 13.55B Yuan, Interim Dividend at 16.00 HK Cents

CSPC Pharmaceutical Group on Smartkarma

Analysts on Smartkarma, like Tina Banerjee, are providing coverage on CSPC Pharmaceutical Group (1093 HK). In a recent report titled “CSPC Pharmaceutical (1093 HK): Deep Value High Dividend Yield Idea; New Launches to Drive Growth,” the analysis highlighted the company’s steady growth in finished drugs in 2023. New product launches such as Mingfule, Yilouda, and Anfulike have contributed to sales ramp-up. CSPC Pharmaceutical plans to introduce 50 innovative drugs over the next five years, aiming for continuous growth momentum. With shares trading at a low P/E ratio of 11.3x, the company is positioned as a value pick with a dividend yield of over 4%.

A look at CSPC Pharmaceutical Group Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Analysts at Smartkarma have assigned CSPC Pharmaceutical Group a range of scores across various categories that are crucial for long-term investment decisions. With a top score of 5 in Dividend and strong scores in Growth and Resilience at 4, the company demonstrates stability and potential for growth in the pharmaceutical industry. These scores reflect positively on CSPC’s ability to provide consistent returns to investors while also indicating solid growth opportunities and a resilient business model.

Although the company scored slightly lower in Value and Momentum at 3, the overall outlook for CSPC Pharmaceutical Group appears promising, with a balanced combination of dividend strength, growth potential, and resilience. As a manufacturer and seller of pharmaceutical products, including key items like vitamin C, antibiotics, and generic drugs, CSPC is also involved in cutting-edge drug development. This diversified portfolio positions the company well for long-term success in the competitive healthcare sector.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma